Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $99,950.76 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Karen M. Anderson sold 5,876 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $17.01, for a total transaction of $99,950.76. Following the transaction, the insider now owns 71,525 shares of the company’s stock, valued at approximately $1,216,640.25. The trade was a 7.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA opened at $16.51 on Thursday. Centessa Pharmaceuticals plc has a one year low of $6.65 and a one year high of $18.97. The company has a market cap of $2.18 billion, a PE ratio of -10.79 and a beta of 1.52. The stock has a 50-day moving average of $16.58 and a 200-day moving average of $13.49. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. On average, equities research analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Institutional Trading of Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. First Light Asset Management LLC lifted its stake in shares of Centessa Pharmaceuticals by 59.2% in the second quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock valued at $43,168,000 after buying an additional 1,778,515 shares in the last quarter. Perceptive Advisors LLC lifted its position in Centessa Pharmaceuticals by 27.6% in the 2nd quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company’s stock valued at $35,518,000 after acquiring an additional 850,000 shares in the last quarter. FMR LLC boosted its stake in Centessa Pharmaceuticals by 4.6% during the 3rd quarter. FMR LLC now owns 2,916,494 shares of the company’s stock valued at $46,635,000 after purchasing an additional 129,300 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in Centessa Pharmaceuticals by 54.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock worth $43,423,000 after purchasing an additional 953,659 shares in the last quarter. Finally, Franklin Resources Inc. raised its stake in shares of Centessa Pharmaceuticals by 99.1% in the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock worth $38,360,000 after purchasing an additional 1,145,823 shares during the last quarter. Institutional investors own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CNTA. BMO Capital Markets increased their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, September 16th. Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. B. Riley started coverage on Centessa Pharmaceuticals in a research note on Thursday, September 19th. They issued a “buy” rating and a $33.00 price objective on the stock. Jefferies Financial Group upped their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Finally, Guggenheim lifted their target price on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.